⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

June 9, 2026Neurology

A Novel Mechanism for the Treatment of Autoimmune Neurologic Diseases: Robust, Rapid, and Tunable Removal of IgG with the MoDE™ Degrader BHV-1300 (P5-2.004)

Bharat Awsare Volkan Granit Eric Ashbrenner Randall Killingsworth Richard Bertz Bruce Car David Spiegel Tova Gardin Vladimir Coric

View at Publisher

Ask AI

Bookmark

Share

Key Points

Assess the safety and pharmacokinetics of BHV-1300 in treating autoimmune neurologic diseases.
Evaluated the pharmacodynamic effects of BHV-1300.
Conducted assessments of safety and efficacy in trial participants.
BHV-1300 demonstrated significant safety profiles in administered doses.
Clinical markers showed favorable pharmacokinetic behaviors, indicating effective IgG removal.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Assesses safety and pharmacodynamic markers of BHV-1300 in autoimmune disease treatment, suggesting new avenues for therapy.

Abstract

Key objectives included assessments of safety, pharmacokinetics, and pharmacodynamic markers of BHV-1300.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Awsare et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f056656 https://doi.org/10.1212/wnl.0000000000216812

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Novel Bispecific Degrader BHV-1300 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models Including Nonhuman Primates (S43.004)2024
2Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating DiseaseOriginal Research · 2020 · 35 citations
3Engineered Nanobodies as Tools to Visualize and Direct Antigen-Specific Tolerance 31162025
4Decoding Antigen-specific Tolerance Mechanisms Imposed by an MHC-II targeted Nanobody-based Therapy for Multiple Sclerosis 2331736Original Research · 2026
5Tolerance induction by PLGA-encapsulated human MOG in a B cell- and antibody-driven model of Experimental Autoimmune Encephalomyelitis 28642025
6A novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trialBlinded Clinical Trial · 2026
7Induction of immune tolerance in NMOSD and MOGAD2025 · 11 citations
8Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific proteinOriginal Research · 2024 · 15 citations
9Statin-induced Myopathy Beyond the Surface: Immune-mediated Necrotizing Myopathy Triggered by CYP3A4 InteractionNeurology · 2026
10Sex Differences in Blood Pressure Dynamics and Outcomes After Endovascular ThrombectomyNeurology · 2026

More from Neurology

More from Yale University

More from Biohaven Pharmaceuticals (United States)